|1.||Nishino, Ichizo: 8 articles (05/2014 - 03/2004)|
|2.||Hinderlich, Stephan: 8 articles (02/2012 - 05/2004)|
|3.||Kohno, Kimitoshi: 8 articles (02/2007 - 04/2002)|
|4.||Hayashi, Yukiko K: 7 articles (05/2014 - 03/2004)|
|5.||Krause, Sabine: 5 articles (09/2015 - 12/2003)|
|6.||Mitrani-Rosenbaum, Stella: 5 articles (06/2014 - 05/2004)|
|7.||Jacobson, Kenneth A: 5 articles (05/2014 - 06/2003)|
|8.||Noguchi, Satoru: 5 articles (05/2014 - 03/2004)|
|9.||Huizing, Marjan: 5 articles (11/2011 - 03/2004)|
|10.||Reutter, Werner: 5 articles (07/2009 - 05/2004)|
|1.||Hepatocellular Carcinoma (Hepatoma)
01/01/2015 - "Drug-Metabolizing Activity, Protein and Gene Expression of UDP-Glucuronosyltransferases Are Significantly Altered in Hepatocellular Carcinoma Patients."
12/01/1987 - "(3) A human hepatoma cell line (Hep G2) was studied to obtain information on the inducibility of human UDP-GT activities by 3-methylcholanthrene-type inducers. "
06/15/1990 - "However, in some hepatocyte nodules and hepatocellular carcinomas either the Mr 55,000 or a new Mr 53,000 polypeptide was preferentially increased, suggesting heterogeneous UDP-GT forms in liver nodules and carcinomas. "
06/25/1989 - "The FDC-6-nonreactive synthetic peptide containing the VTHPGY sequence was converted into FDC-6-reactive form on incubation with alpha-N-acetylgalactosaminyltransferase and UDP-[3H]GalNAc in the homogenate of hepatoma cell HUH-7, human fetal fibroblast cell line WI-38, or human epidermoid carcinoma cell line A431. "
01/09/2015 - "Furthermore, UDP-N-acetyl-α-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase-10 (GALNT10) was identified as a bona fide target of miR-122 in hepatoma cells. "
12/15/1992 - "In this study, membranes of patients' affected T cells were labeled with UDP-[3H]GlcNAc to evaluate earlier steps in GPI synthesis, and intact cells were fused to Thy-1- murine lymphoma mutants harboring different defects in early GPI assembly to test for the presence of corresponding or complementary lesions. "
05/15/1994 - "We have used a similar method with UDP-[3H]Gal to obtain glycosyltransferase product profiles from several human leukemia/lymphoma cell lines and subsequently identify two galactosyltransferase activities in these cell lines: UDP-Gal:Gal beta 1-4Glc beta 1-1Cer alpha 1,4galactosyltransferase; and UDP-Gal:GlcNAc beta 1--3Gal beta 1--4Glc beta 1--1Cer beta 1,4galactosyltransferase. "
05/05/1993 - "Addition of this nucleotide triphosphate to incubations in which GPI precursors were synthesized from UDP-[6-3H]GlcNAc by microsomes prepared from the lymphoma cell line EL4 resulted in a shift in the relative amount of each intermediate formed such that [6-3H]GlcN-PI was the predominant product. "
11/25/1982 - "A mouse lymphoma cell line resistant to the leukoagglutinating lectin from Phaseolus vulgaris is deficient in UDP-GlcNAc: alpha-D-mannoside beta 1,6 N-acetylglucosaminyltransferase."
06/14/1976 - "Saline extraction of tumor cells from YC8 lymphoma transplanted in Balb/c Mice, of lymphocytes from animals bearing this tumor and of lymphocytes from control animals, allowed us to show important hydrolytic activities towards UDP-[(14C)]-galactose and galactose-[(14C)]-1-phosphate in normal lymphocytes. "
|3.||Small Cell Lung Carcinoma (Small Cell Lung Cancer)
01/01/2015 - "To analyze the distribution of uridine diphosphate glucuronosyltransferase (UGT)1A1 gene polymorphisms in Chinese patients with extensive-stage small-cell lung cancer (E-SCLC), and to evaluate correlations between the UGT1A1 gene polymorphisms and toxicity, and efficacy of irinotecan (CPT-11) based regimen in the patients with E-SCLC. "
11/01/2014 - "The aim was to investigate the association between uridine diphosphate glucuronide transferase 1A1 (UGT1A1) gene promoter region polymorphism and irinotecan-related adverse effects and efficacy on recurrent and refractory small cell lung cancer (SCLC). "
11/01/2014 - "Uridine diphosphate glucuronide transferase 1A1FNx0128 gene polymorphism and the toxicity of irinotecan in recurrent and refractory small cell lung cancer."
07/01/1992 - "UDP-N-acetylhexosamine modulation by glucosamine and uridine in NCI N-417 variant small cell lung cancer cells: 31P nuclear magnetic resonance results."
11/01/2015 - "This study evaluated the efficacy and safety of irinotecan/cisplatin (IP) and etoposide/cisplatin (EP) in extensive-stage small cell lung cancer (ES-SCLC) and the distribution of uridine diphosphate glucuronosyltransferase (UGT1A1). "
02/01/2011 - "211 G to a variation of UDP-glucuronosyl transferase 1A1 gene and neonatal breastfeeding jaundice."
11/01/1993 - "Human UDP-glucuronosyl transferases: chemical defence, jaundice and gene therapy."
01/01/2012 - "Clearance of bilirubin requires the expression of uridine diphosphate glucuronosyltransferase (UGT) 1A1; we investigated its role in the association between breast feeding with jaundice in mice. "
07/01/2014 - "Bilirubin uridine diphosphate-glucuronosyltransferase variation is a genetic basis of breast milk jaundice."
08/01/1999 - "Intermittent jaundice in patients with acute leukaemia: a common mutation of the bilirubin uridine-diphosphate glucuronosyltransferase gene among Asians."
|5.||Post-Dural Puncture Headache
11/01/2001 - "To assess the time of occurrence, circumstances and presenting symptoms of unintentional dural puncture (UDP), the location and intensity of postdural puncture headaches (PDPH), and the efficacy of their treatment by epidural blood-patch (EBP). "
09/01/1999 - "To determine the association between bearing down, postdural puncture headache (PDPH) and epidural blood patch (EBP) following single 17 gauge unintentional dural puncture (UDP) in parturients. "
05/01/2015 - "Unintentional dural puncture (UDP) and postdural puncture headache (PDPH) occur during the course of epidural catheter placement for labor analgesia with a reported incidence of 1%-5%. "
|1.||Glucuronosyltransferase (UDP Glucuronosyltransferase)
|5.||Cytochrome P-450 Enzyme System (Cytochrome P450)
|6.||Etoposide (VP 16)
|1.||Epidural Blood Patch
|2.||Prostheses and Implants (Prosthesis)
|3.||Combination Drug Therapy (Combination Chemotherapy)
|4.||Drug Therapy (Chemotherapy)